日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations.

RANKL/PD-1 双重阻断疗法可提高携带 KRAS 突变的晚期肺腺癌患者的生存率

期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2025.102235
Li Hong-Shuai, Liu Cheng-Ming, Zheng Su-Fei, Wu Peng, Xu Han-Yan, Hao Xue-Zhi, Li Jun-Ling, Xing Pu-Yuan, Duan Jian-Chun, Wang Zhi-Jie, Zhong Jia, Tian Lin-Yan, Cui Yan-Yan, Fang Qin, Lei Si-Yu, Wang Si-Hui, Luo Yue-Jun, Wang Zhan-Yu, Wang Jie, He Jie, Sun Nan, Wang Yan
肿瘤
肺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)

携带 21 号外显子 L858R 突变的非小细胞肺癌患者：从不同的机制到表皮生长因子受体酪氨酸激酶抑制剂治疗（综述）

期刊:Oncology Letters
影响因子:2.2
doi:10.3892/ol.2024.14855
Liu, Jia-Yu; Wang, Shou-Zheng; Yuan, Han-Qi; Li, Jun-Ling; Xing, Pu-Yuan
肺癌
肿瘤
肿瘤免疫
信号转导
细胞生物学
发表日期：2025
文献求助 收藏

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer

PD-L1表达对EGFR突变型非小细胞肺癌中EGFR-TKI疗效的影响

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.15021
Lei, Si-Yu; Xu, Hai-Yan; Li, Hong-Shuai; Yang, Ya-Ning; Xu, Fei; Li, Jun-Ling; Wang, Zhi-Jie; Xing, Pu-Yuan; Hao, Xue-Zhi; Wang, Yan
肺癌
肿瘤
肿瘤免疫
EGF
PD-L1
EGFR
细胞生物学
发表日期：2023
文献求助 收藏

A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations

一项关于达克替尼在携带EGFR突变的晚期非小细胞肺癌患者后线治疗中的真实世界研究

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.4495
Li, Hong-Shuai; Zhang, Jin-Yao; Yan, Xiang; Xu, Hai-Yan; Hao, Xue-Zhi; Xing, Pu-Yuan; Wang, Yan
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2022
文献求助 收藏

Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis

小细胞肺癌中循环肿瘤细胞（CTC）/循环肿瘤内皮细胞（CTEC）及其亚型：疗效和预后的预测因子

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.14120
Zhu, Hao-Hua; Liu, Yu-Tao; Feng, Yu; Zhang, Li-Na; Zhang, Tong-Mei; Dong, Gui-Lan; Xing, Pu-Yuan; Wang, Hong-Yu; Shi, Yuan-Kai; Hu, Xing-Sheng
肺癌
肿瘤
肿瘤免疫
TEC
内皮细胞
细胞生物学
肿瘤细胞
发表日期：2021
文献求助 收藏

Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study

中国非小细胞肺癌患者化疗使用情况的变化及其影响因素：一项多中心10年（2005-2014年）回顾性研究

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S253789
Xing, Pu-Yuan; Wang, Shou-Zheng; Shi, Ju-Fang; Wang, Le; Hui, Zhou-Guang; Ren, Jian-Song; Liu, Shang-Mei; Qiao, You-Lin; Dai, Min; Li, Jun-Ling
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI

在接受 EGFR-TKI 治疗的晚期非小细胞肺癌患者中，反应深度与无进展生存期相关。

期刊:Journal of Cancer
影响因子:3.2
doi:10.7150/jca.33450
Liu, Yu-Tao; Zhang, Kai; Li, Cheng-Cheng; Hu, Xing-Sheng; Jiang, Jun; Hao, Xue-Zhi; Wang, Yan; Li, Jun-Ling; Xing, Pu-Yuan; Yang, Sheng; Zhang, Xin; Wang, Guo-Qiang; Cai, Shang-Li; Shi, Yuan-Kai
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2019
文献求助 收藏

Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer

白蛋白结合型紫杉醇治疗复发性晚期非小细胞肺癌的疗效和安全性

期刊:Chinese Journal of Cancer Research
影响因子:6.3
doi:10.3978/j.issn.1000-9604.2013.03.04
Xing, Pu-Yuan; Li, Jun-Ling; Wang, Yan; Hao, Xue-Zhi; Wang, Bin; Yang, Lin; Shi, Yuan-Kai; Zhang, Xiang-Ru
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2013
文献求助 收藏